Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Blood (2025) 146 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2025-2838

Published: 2025

Journal Articles

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study

Blood (2025) 146 (Supplement 1): 882.

https://doi.org/10.1182/blood-2025-882

Published: 2025

Journal Articles

Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia

Harinder Gill, Farhad Ravandi, Jessica Altman, Gail Roboz, Tony Wu, Garret Leung, Danelle James, Stephane Berthier, Yok-Lam Kwong

Blood (2025) 146 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2025-1506

Published: 2025

Journal Articles

A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress

Kuo-Kai Chin, Andriy Derkach, Leora Boussi, Gabrielle Melamed, Giulia Petrone, Kelly Bolton, Maher Abdul Hay, Jessica Altman, Andrew Intlekofer, Eytan Stein

Blood (2025) 146 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2025-1690

Published: 2025

Journal Articles

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Eytan Stein, Alice Mims, Zhuoer Xie, Gabriel Mannis, Justin Watts, Farhad Ravandi, Gary Schiller, Brian Ball, Hongtao Liu, Jessica Altman, Eunice Wang, J. Jean Cui, Jihao Zhou, Zachary Zimmerman, Stephen Strickland

Blood (2025) 146 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2025-1655

Published: 2025

Journal Articles

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Kuo-Kai Chin, Brian Ball, Yasmin Abaza, Jessica Altman, Rahul Thakur, Moiez Ali, Andriy Derkach, Mark Geyer, Aaron Goldberg, Tamanna Haque, Meghan Thompson, Jae Park, Martin Tallman, Sheng Cai, Eunice Wang, Ibrahim Aldoss, Eytan Stein

Blood (2025) 146 (Supplement 1): 39.

https://doi.org/10.1182/blood-2025-39

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood (2025) 146 (Supplement 1): 766.

https://doi.org/10.1182/blood-2025-766

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Blood (2025) 146 (Supplement 1): 654.

https://doi.org/10.1182/blood-2025-654

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 651.

https://doi.org/10.1182/blood-2025-651

Published: 2025

Journal Articles

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

Blood (2016) 128 (22): 2745.

https://doi.org/10.1182/blood.V128.22.2745.2745

Published: 2016

Journal Articles

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Jason B Kaplan, MD, Dale L. Bixby, MD, John C Morris, MD, Olga Frankfurt, MD, Jessica Altman, Trisha Wise-Draper, MD PhD, Patrick W. Burke, MD, Sabrina Collins, BS, Karuppiah Kannan, PhD, Ling Wang, PhD, Stephanie Faucette, PharmD, PhD, Benjamin Lee, MD PhD, Yaping Shou, MD PhD, Mark J. Levis, MD PhD, Keith W. Pratz, MD

Blood (2016) 128 (22): 2834.

https://doi.org/10.1182/blood.V128.22.2834.2834

Published: 2016

Journal Articles

Idarubicin Appears Equivalent to Dose-Intense daunorubicin for AML Induction

Steven Trifilio, Zheng Zhou, Jayesh Mehta, MD, Colleen Czerniak, Judy Pi, Molly Koslosky, Deborah Greenberg, Mihaela Pantiru, MD, Jessica Altman

Blood (2012) 120 (21): 3581.

https://doi.org/10.1182/blood.V120.21.3581.3581

Published: 2012

Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.

Guillermo Garcia-Manero, MD, Selina Luger, MD, Parameswaran Venugopal, MD, Lori J. Maness, MD, Meir Wetzler, MD, Jessica Altman, MD, David F. Claxton, M.D., Stephen Strickland, MD, Stefan Faderl, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 1758.

https://doi.org/10.1182/blood.V114.22.1758.1758

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia

A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Idarubicin Appears Equivalent to Dose-Intense daunorubicin for AML Induction

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only